Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2018

View Archived Issues

AzurRx BioPharma's AZ-1103 safe and biologically active in preclinical model

Pfizer enrolling patients in phase III trial of glasdegib for the treatment of AML

Merck KGaA presents potent and selective ATM kinase inhibitor M-3541

FDA clears IND application for phase I/II study of OBI-3424

KB-103 receives orphan medicinal product designation in Europe

Shire and Takeda in discussions after Shire rejects three Takeda proposals for company

Pfizer's novel ADC CD123-CPI has broad potential for treating acute myeloid leukemia

FDA grants orphan drug designation for Oraxol for the treatment of angiosarcoma

Argos Therapeutics discontinues ADAPT study based on interim analysis results

FDA grants fast track designation for balixafortide plus eribulin for metastatic breast cancer

Phase II E4 Relief study of Donesta achieves primary objective

ApolloBio obtains license to Toca 511/Toca FC for greater China region

CD163, VCAM-1 identified as markers of liver injury in autoimmune hepatitis

Goofice tablet launched in Japan

Otsuka launches Rexulti in Japan

First-in-human study of FS-118 in advanced solid tumors enrolling subjects

FDA accepts Veloxis' sNDA for Envarsus XR

ADC Therapeutics presents potent antitumoral compounds in xenograft models

Johnson & Johnson reviews progress of first quarter 2018

FDA advisory committee recommends approval of Epidiolex for LGS and Dravet syndrome

Novel genetically altered broadly neutralizing antibodies protect monkeys from SHIV

EMA committee hands down negative opinion for masitinib in ALS

Relay Therapeutics and collaborator patent PTP-2C inhibitors

Plexxikon divulges novel IDO1 and/or TDO inhibitors

Vertex Pharmaceuticals identifies new PAR-2 antagonists

Medshine Discovery patents MAPK 14 inhibitors

Mission Therapeutics presents novel USP30 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...